Results 11 to 20 of about 9,744,428 (293)

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling [PDF]

, 2004
Background: We have shown previously that whereas overexpression of human epidermal growth factor receptor (HER) 1, HER2 and HER3 is associated with poor prognosis in breast cancer, HER4 is associated with a good prognosis.
Reeves, J.R., Cooke, T.G., Witton, C.J., Tovey, S.M., Bartlett, J.M.S., Stanton, P.D.   +5 more
core   +10 more sources

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Therapeutics and Clinical Risk Management, 2008
Daanish Hoda1, George R Simon1, Christopher R Garrett1,21Division of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Current affiliation: Department of Gastrointestinal Oncology, The University of Texas ...
Daanish Hoda, George R Simon, Christopher R Garrett   +2 more
doaj   +1 more source

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Biologics: Targets & Therapy, 2009
Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies.
Bryan A Faller, Barbara Burtness
doaj   +2 more sources

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations

International Journal of Women's Health, 2014
Nathan WD Lamond, Tallal YounisDepartment of Medicine, Dalhousie University at the Queen Elizabeth II Health Sciences Centre, Halifax, NS, CanadaAbstract: In the absence of specific therapy, the 15%–20% of breast cancers demonstrating human ...
Lamond NW, Younis T
doaj   +1 more source

Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer

Contemporary Oncology, 2022
INTRODUCTION: For epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC), no studies have treated the site of recurrence after first-line tyrosine kinase inhibitor (TKI) treatment as a “metastasis pattern”.
Shinichiro Okauchi, Kunihiko Miyazaki, Hiroaki Satoh   +2 more
doaj   +2 more sources

Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease

Neural Regeneration Research, 2022
Numerous molecular mechanisms are being examined in an attempt to discover disease-modifying drugs to slow down the underlying neurodegeneration in Alzheimer’s disease.
Heba M Mansour, Hala M Fawzy, Aiman S El-Khatib, Mahmoud M Khattab   +3 more
doaj   +1 more source

Potency and stability of C terminal truncated human epidermal growth factor [PDF]

, 2000
INTRODUCTION: Epidermal growth factor (EGF) is normally present as EGF(1-53). A variety of C terminal truncated forms have been used in preliminary trials for treating gastrointestinal injury but their relative potency and stability when used in a ...
Lakhoo, K, Berlanga-Acosta, J, Edwards, A. D.; id_orcid, Marchbank, T, Edwards, AD, Fagbemi, A., Calnan, D. P., Sizer, T., Berlanga-Acosta, J., Fagbemi, A, Marchbank, T., Sizer, T, Playford, RJ, Playford, R. J., Lakhoo, K., Calnan, DP   +15 more
core   +4 more sources

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Journal of Medical Case Reports, 2020
Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations.
Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda   +8 more
doaj   +1 more source

Outcome of Epidermal Growth Factor Receptor Mutated and Non Mutated Adenocarcinoma Lung to Standard Therapy

Journal of Nepal Health Research Council, 2023
Background: Asian patients with adenocarcinoma of lung have higher incidence of epidermal growth factor receptor mutations which predict increased response and survival in patients to oral tyrosine kinase inhibitors.
Soniya Dulal, Akshat Mishra, Aarati Shah, Bibek Acharya, Ramila Shilpakar, Sandhya Chapagain Acharya, Ambuj Karn, Rajeev Sharma, Balram Gautam, Bishnu Dutta Paudel   +9 more
doaj   +1 more source

Targeting the epidermal growth factor receptor [PDF]

British Journal of Cancer, 2004
The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptors (RTK). The EGFR is involved in cell proliferation, metastasis and angiogenesis, and is expressed in a large proportion of epithelial tumours. The two main classes of EGFR inhibitors in clinical trials are the RTK inhibitors and the monoclonal ...
El-Rayes, B F, LoRusso, P M
openaire   +2 more sources